Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs
1. Axsome’s EMERGE Phase 3 trial met its primary endpoint. Data shows robust efficacy. 2. Symbravo achieved a superior mTOQ-4 score (5.2 vs 2.8). Results were statistically significant. 3. Patients reported rapid pain freedom and sustained relief over 24 hours. Daily activity restoration improved markedly. 4. Trial outcomes indicate potential market advantage over standard oral CGRP inhibitors. Positive clinical trends noted.